N
INO icon

Natixis’s Inovio Pharmaceuticals INO Stock Holding History

Natixis’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,508
Closed -$613K – 1240
2021
Q2 		$613K Buy
+5,508
New +$529K ﹤0.01% 683
2021
Q1 		– Sell
-1,458
Closed -$155K – 1124
2020
Q4 		$155K Buy
+1,458
New +$194K ﹤0.01% 1010
2014
Q1 		– Sell
-221
Closed -$30K – 560
2013
Q4 		$30K Sell
221
-56
-20% -$5.6K ﹤0.01% 556
2013
Q3 		$28K Buy
+277
New +$23.2K ﹤0.01% 483

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Natixis's INO Position: Q3 2021 in Review

Natixis sold out of Inovio Pharmaceuticals (INO) in Q3 2021, closing a stake of 5,508 shares — an estimated $613K sold.

Natixis first reported a position in INO in Q3 2013 and held it in 4 quarters. The position peaked at $613K in Q2 2021. 213 funds tracked by Wall St. Rank hold INO as of Q3 2021.

  • Natixis reported no remaining Inovio Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Natixis sold 5,508 Inovio Pharmaceuticals shares in Q3 2021, an estimated $613K.
  • Natixis first reported a position in Inovio Pharmaceuticals in Q3 2013 and held it in 4 quarters.
  • Natixis's Inovio Pharmaceuticals position peaked at $613K in Q2 2021.
  • 213 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2021.

Based on Natixis's 13F filing for Q3 2021, filed 12 Nov 2021.